Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Klebsiella Infections | 4 | 2018 | 466 | 1.09 | Why? |
| Bacteremia | 6 | 2019 | 1372 | 1.01 | Why? |
| beta-Lactams | 4 | 2019 | 210 | 1.00 | Why? |
| Organ Transplantation | 4 | 2021 | 2616 | 0.90 | Why? |
| Klebsiella pneumoniae | 5 | 2018 | 658 | 0.89 | Why? |
| beta-Lactam Resistance | 2 | 2019 | 150 | 0.78 | Why? |
| Antifungal Agents | 3 | 2018 | 1828 | 0.75 | Why? |
| beta-Lactamase Inhibitors | 2 | 2019 | 104 | 0.75 | Why? |
| Carbapenems | 2 | 2019 | 343 | 0.69 | Why? |
| Echinocandins | 1 | 2018 | 139 | 0.65 | Why? |
| Candidemia | 2 | 2018 | 353 | 0.65 | Why? |
| Transplant Recipients | 4 | 2021 | 4982 | 0.65 | Why? |
| Sepsis | 3 | 2018 | 3517 | 0.62 | Why? |
| Microbiological Techniques | 1 | 2018 | 232 | 0.62 | Why? |
| Enterobacteriaceae Infections | 2 | 2019 | 529 | 0.61 | Why? |
| Anti-Bacterial Agents | 10 | 2019 | 10083 | 0.59 | Why? |
| Minocycline | 4 | 2018 | 101 | 0.53 | Why? |
| Invasive Fungal Infections | 1 | 2018 | 274 | 0.52 | Why? |
| Chemoprevention | 1 | 2018 | 585 | 0.50 | Why? |
| Preoperative Care | 1 | 2020 | 1515 | 0.41 | Why? |
| Heart Transplantation | 1 | 2020 | 1293 | 0.40 | Why? |
| Thienamycins | 3 | 2018 | 72 | 0.39 | Why? |
| Gastrointestinal Microbiome | 1 | 2021 | 1961 | 0.35 | Why? |
| Shock, Septic | 1 | 2017 | 1313 | 0.34 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 3 | 2018 | 214 | 0.33 | Why? |
| Azabicyclo Compounds | 2 | 2018 | 91 | 0.33 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.32 | Why? |
| Ceftazidime | 2 | 2018 | 134 | 0.32 | Why? |
| Liver Transplantation | 2 | 2018 | 2864 | 0.29 | Why? |
| Colistin | 2 | 2017 | 217 | 0.28 | Why? |
| Risk Factors | 11 | 2020 | 71621 | 0.27 | Why? |
| Drug Resistance, Multiple, Bacterial | 4 | 2019 | 1115 | 0.25 | Why? |
| Communicable Diseases | 1 | 2017 | 2148 | 0.24 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.23 | Why? |
| Disease Management | 2 | 2019 | 6841 | 0.22 | Why? |
| Gentamicins | 2 | 2017 | 76 | 0.21 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.20 | Why? |
| Cross Infection | 3 | 2019 | 8675 | 0.18 | Why? |
| Heart Failure | 1 | 2020 | 6638 | 0.18 | Why? |
| RNA, Ribosomal, 16S | 1 | 2021 | 793 | 0.17 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.17 | Why? |
| Italy | 11 | 2021 | 38444 | 0.17 | Why? |
| Liver Cirrhosis | 2 | 2019 | 1810 | 0.17 | Why? |
| Intraabdominal Infections | 1 | 2018 | 90 | 0.17 | Why? |
| Meningitis, Viral | 1 | 2018 | 97 | 0.16 | Why? |
| Meningitis, Bacterial | 1 | 2018 | 111 | 0.16 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| Pulmonary Aspergillosis | 1 | 2021 | 408 | 0.16 | Why? |
| Acinetobacter Infections | 1 | 2019 | 273 | 0.15 | Why? |
| Glycopeptides | 1 | 2018 | 199 | 0.15 | Why? |
| Acinetobacter baumannii | 1 | 2019 | 378 | 0.15 | Why? |
| Antibiotic Prophylaxis | 1 | 2018 | 399 | 0.14 | Why? |
| Automation, Laboratory | 1 | 2018 | 536 | 0.14 | Why? |
| beta-Lactamases | 2 | 2018 | 759 | 0.14 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2018 | 711 | 0.14 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2021 | 634 | 0.14 | Why? |
| Plasmids | 1 | 2017 | 840 | 0.13 | Why? |
| Analysis of Variance | 1 | 2017 | 950 | 0.13 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.13 | Why? |
| Encephalitis, Viral | 1 | 2018 | 355 | 0.13 | Why? |
| Liver Failure, Acute | 1 | 2017 | 279 | 0.13 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 2018 | 881 | 0.13 | Why? |
| Incidence | 4 | 2019 | 25622 | 0.12 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.12 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.12 | Why? |
| Multivariate Analysis | 2 | 2020 | 5440 | 0.12 | Why? |
| Prospective Studies | 6 | 2021 | 43301 | 0.12 | Why? |
| Aged | 14 | 2021 | 215776 | 0.11 | Why? |
| Staphylococcal Infections | 2 | 2018 | 1099 | 0.11 | Why? |
| Survival Analysis | 3 | 2020 | 7592 | 0.11 | Why? |
| Middle Aged | 16 | 2020 | 270681 | 0.11 | Why? |
| Graft Rejection | 2 | 2018 | 1766 | 0.10 | Why? |
| Clostridium Infections | 1 | 2018 | 595 | 0.10 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.10 | Why? |
| Humans | 30 | 2021 | 930598 | 0.10 | Why? |
| Prosthesis-Related Infections | 1 | 2014 | 302 | 0.10 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 1439 | 0.10 | Why? |
| Multimodal Imaging | 1 | 2014 | 534 | 0.10 | Why? |
| Male | 18 | 2020 | 367725 | 0.09 | Why? |
| Respiratory Insufficiency | 2 | 2020 | 7301 | 0.09 | Why? |
| Microbial Sensitivity Tests | 4 | 2018 | 2886 | 0.09 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.09 | Why? |
| Endocarditis, Bacterial | 1 | 2014 | 344 | 0.09 | Why? |
| Logistic Models | 2 | 2020 | 9089 | 0.09 | Why? |
| Female | 17 | 2020 | 380317 | 0.09 | Why? |
| Positron-Emission Tomography | 1 | 2014 | 802 | 0.09 | Why? |
| Aged, 80 and over | 7 | 2020 | 88759 | 0.09 | Why? |
| Heart Valve Prosthesis | 1 | 2014 | 533 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.09 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.08 | Why? |
| Treatment Outcome | 5 | 2020 | 51732 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| Candida albicans | 2 | 2018 | 217 | 0.07 | Why? |
| Retrospective Studies | 8 | 2020 | 105322 | 0.07 | Why? |
| Infusions, Intravenous | 2 | 2019 | 1224 | 0.07 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.07 | Why? |
| Evolution, Molecular | 1 | 2018 | 3691 | 0.07 | Why? |
| Hospitals | 3 | 2020 | 11793 | 0.06 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.06 | Why? |
| Tertiary Care Centers | 2 | 2019 | 8248 | 0.06 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.06 | Why? |
| Adult | 12 | 2021 | 244371 | 0.06 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.06 | Why? |
| Candidiasis | 2 | 2018 | 334 | 0.06 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.05 | Why? |
| Adolescent | 4 | 2020 | 86841 | 0.05 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.05 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.05 | Why? |
| Piperacillin | 1 | 2019 | 63 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.05 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.05 | Why? |
| Bacterial Proteins | 2 | 2018 | 1318 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Porins | 1 | 2018 | 45 | 0.05 | Why? |
| Drug Combinations | 2 | 2018 | 3852 | 0.04 | Why? |
| Ethambutol | 1 | 2017 | 34 | 0.04 | Why? |
| Imipenem | 1 | 2017 | 57 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2020 | 6543 | 0.04 | Why? |
| Bacteria | 2 | 2018 | 1897 | 0.04 | Why? |
| Fungemia | 1 | 2018 | 86 | 0.04 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.04 | Why? |
| Isoniazid | 1 | 2017 | 105 | 0.04 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.04 | Why? |
| Cephalosporins | 1 | 2017 | 250 | 0.04 | Why? |
| Postoperative Complications | 1 | 2014 | 5861 | 0.04 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.04 | Why? |
| Patient Outcome Assessment | 1 | 2019 | 707 | 0.04 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Fluorine Radioisotopes | 1 | 2014 | 59 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.03 | Why? |
| Reoperation | 1 | 2014 | 544 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Hospital Mortality | 3 | 2020 | 22087 | 0.03 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.03 | Why? |
| Internal Medicine | 1 | 2016 | 557 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.02 | Why? |
| Radiopharmaceuticals | 1 | 2014 | 763 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Endocarditis | 1 | 2014 | 368 | 0.02 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2017 | 2309 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.02 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2014 | 552 | 0.02 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.02 | Why? |
| Aortic Valve | 1 | 2014 | 664 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| False Negative Reactions | 1 | 2014 | 1785 | 0.02 | Why? |
| Tomography, X-Ray Computed | 1 | 2014 | 25144 | 0.02 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.02 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2014 | 1153 | 0.02 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.02 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.02 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2014 | 3395 | 0.02 | Why? |
| Viruses | 1 | 2018 | 2238 | 0.02 | Why? |
| Intensive Care Units | 2 | 2021 | 29594 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Child | 2 | 2020 | 70012 | 0.01 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
Giannella's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(178)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(196)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_